Piper Sandler Companies
- Average 12 Month ROI on "Buy" Recommendations
- 63.482%
- Based on
- 130 research note(s)
- MarketBeat Brokerage Ranking
- 5 of 5 stars
Recent Recommendations from Piper Sandler Companies
- Accenture plc (NYSE: ACN) had its "neutral" rating re-affirmed by analysts at Piper Sandler Companies. They now have a $329.00 price target on the stock. (9/20/2024)
- Abbott Laboratories (NYSE: ABT) is now covered by analysts at Piper Sandler Companies. They set an "overweight" rating and a $131.00 price target on the stock. (9/19/2024)
- Acrivon Therapeutics, Inc. (NASDAQ: ACRV) had its "buy" rating re-affirmed by analysts at Piper Sandler Companies. They now have a $30.00 price target on the stock. (9/6/2024)
- C3.ai, Inc. (NYSE: AI) had its "neutral" rating re-affirmed by analysts at Piper Sandler Companies. They now have a $24.00 price target on the stock. (9/5/2024)
- Aadi Bioscience, Inc. (NASDAQ: AADI) was downgraded by analysts at Piper Sandler Companies from an "overweight" rating to a "neutral" rating. They now have a $1.75 price target on the stock. (8/27/2024)